WuXi AppTec's 2025 interim report: both revenue and net profit doubled, attributed net profit surged by 56%.

WuXi Biologics released its mid-term performance in 2025, with revenue reaching RMB 9.95 billion in the first half of the year, a year-on-year increase of 16.1%; net profit increased by 54.8% year-on-year to RMB 2.76 billion, with net profit attributable to shareholders increasing by 56.0% to RMB 2.34 billion; gross profit margin increased by 3.6 percentage points year-on-year to 42.7%, with adjusted gross profit of RMB 4.54 billion. Key factors driving revenue growth include leading technology platforms, industry-best project delivery times and outstanding project execution records, successful implementation of the "follow and win molecules" strategy, and improved utilization of existing and new production capacity. Based on this strong performance growth, WuXi Biologics raised its full-year revenue guidance for 2025 to 14%-16%. In the first half of 2025, WuXi Biologics' R&D, M, and D businesses all achieved rapid growth. In research services, over 50 molecular projects have been empowered, and potential milestone payments and sales royalties in the future will significantly enhance long-term profit growth. In development business, pre-clinical revenue increased by 35.2% year-on-year, with the WuXiaTM patented cell line development platform having rights to receive potential royalties from over 600 projects. In production business, revenue from Phase III clinical trials and commercial production increased by 24.9% year-on-year, with plans to complete 25 PPQs in 2025 to lay a solid foundation for the future development of production business.